These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 31161994)

  • 1. Cardiovascular and Renal Outcomes of Incretin-based Therapies: A Review of Recent Clinical Trials.
    Kyriakos G; Quiles-Sanchez LV; Garmpi A; Farmaki P; Kyre K; Gkogkos S; Savvanis S; Memi E
    Curr Cardiol Rev; 2020; 16(4):253-257. PubMed ID: 31161994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular Effects of Incretin-Based Therapies.
    White WB; Baker WL
    Annu Rev Med; 2016; 67():245-60. PubMed ID: 26768240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular Effect of Incretin-Based Therapy in Patients with Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis.
    Kim JY; Yang S; Lee JI; Chang MJ
    PLoS One; 2016; 11(4):e0153502. PubMed ID: 27078018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular protective properties of incretin-based therapies in type 2 diabetes.
    Simsek S; de Galan BE
    Curr Opin Lipidol; 2012 Dec; 23(6):540-7. PubMed ID: 23160401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus.
    Campbell RK
    Clin Ther; 2011 May; 33(5):511-27. PubMed ID: 21665040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular safety of incretin-based therapy for type 2 diabetes: A meta-analysis of randomized trials.
    Mahmoud AN; Saad M; Mansoor H; Elgendy AY; Barakat AF; Abuzaid A; Mentias A; Elgendy IY
    Int J Cardiol; 2017 Mar; 230():324-326. PubMed ID: 28043676
    [No Abstract]   [Full Text] [Related]  

  • 7. Incretin pharmacology: a review of the incretin effect and current incretin-based therapies.
    Neumiller JJ
    Cardiovasc Hematol Agents Med Chem; 2012 Dec; 10(4):276-88. PubMed ID: 22827291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Efficacy of Incretin-Based Therapies in Patients With Type 2 Diabetes Mellitus and CKD: A Systematic Review and Meta-analysis.
    Howse PM; Chibrikova LN; Twells LK; Barrett BJ; Gamble JM
    Am J Kidney Dis; 2016 Nov; 68(5):733-742. PubMed ID: 27528374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacology of incretin therapies for type 2 diabetes mellitus: implications for treatment.
    Neumiller JJ
    Clin Ther; 2011 May; 33(5):528-76. PubMed ID: 21665041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular actions of incretin-based therapies.
    Ussher JR; Drucker DJ
    Circ Res; 2014 May; 114(11):1788-803. PubMed ID: 24855202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CARDIOVASCULAR OUTCOME TRIALS OF THE INCRETIN-BASED THERAPIES: WHAT DO WE KNOW SO FAR?
    Mora PF; Johnson EL
    Endocr Pract; 2017 Jan; 23(1):89-99. PubMed ID: 27819769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incretin-based therapies: can we achieve glycemic control and cardioprotection?
    Angeli FS; Shannon RP
    J Endocrinol; 2014 Apr; 221(1):T17-30. PubMed ID: 23926280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes.
    Smits MM; Tonneijck L; Muskiet MH; Hoekstra T; Kramer MH; Pieters IC; Cahen DL; Diamant M; van Raalte DH
    BMJ Open; 2015 Nov; 5(11):e009579. PubMed ID: 26586327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implications of incretin-based therapies on cardiovascular disease.
    Rotz ME; Ganetsky VS; Sen S; Thomas TF
    Int J Clin Pract; 2015 May; 69(5):531-49. PubMed ID: 25363540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cardiovascular effect of incretin-based therapies among type 2 diabetes: a systematic review and network meta-analysis.
    Wu S; Cipriani A; Yang Z; Yang J; Cai T; Xu Y; Quan X; Zhang Y; Chai S; Sun F; Zhan S
    Expert Opin Drug Saf; 2018 Mar; 17(3):243-249. PubMed ID: 29320889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes.
    Cornell S
    J Clin Pharm Ther; 2012 Oct; 37(5):510-24. PubMed ID: 22436069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction.
    Russell S
    Int J Clin Pharm; 2013 Apr; 35(2):159-72. PubMed ID: 23263796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differentiating incretin-based therapies for population-based health care.
    Calabrese D
    Am J Manag Care; 2011 Mar; 17(2 Suppl):S52-8. PubMed ID: 21517657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potentials of incretin-based therapies in dementia and stroke in type 2 diabetes mellitus.
    Groeneveld ON; Kappelle LJ; Biessels GJ
    J Diabetes Investig; 2016 Jan; 7(1):5-16. PubMed ID: 26816596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential cardiovascular effects of incretin-based therapies.
    Deacon CF; Marx N
    Expert Rev Cardiovasc Ther; 2012 Mar; 10(3):337-51. PubMed ID: 22390806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.